TMEM167A

Across TCGA pan-cancer cohorts, TMEM167A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TMEM167A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM167A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TMEM167A is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where TMEM167A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM167A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	+0.363	<.001	11	view →
COAD	Female	III,IV	+0.372	<.001	10	view →
LSCC	Female	All	−0.472	<.001	9	view →
PDAC	All	All	−0.655	<.001	5	view →
OV	All	All	+0.621	.003	2	view →
LUAD	Male	All	−0.150	.034	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TMEM167A–CCRCC

Open the CCRCC breakdown →